A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system

Journal of Pharmacology and Experimental Therapeutics

Volumn 317, Issue 3, 2006, Pages 1372-1381

  Ho Lun, Wong ^a   Bendayan, Reina ^a   Rauth, Andrew M ^b   Hui, Yi Xue ^a   Babakhanian, Karlo ^a   Xiao, Yu Wu ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; GLYCOPROTEIN P; LIPID; NANOPARTICLE;

ANIMAL CELL; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL MEMBRANE PERMEABILITY; CELL NUCLEUS MEMBRANE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG INHIBITION; DRUG LABELING; DRUG MECHANISM; DRUG RETENTION; DRUG SCREENING; DRUG UPTAKE; ECHOMAMMOGRAPHY; ENDOCYTOSIS; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PHAGOCYTOSIS; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; DRUG CARRIERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENDOCYTOSIS; FEMALE; HUMANS; LIPIDS; NANOSTRUCTURES; P-GLYCOPROTEIN; POLYMERS;

EID: 33646798446     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.101154     Document Type: Article

References (39)

1. Baldini N, Scotlandi K, Serra M, Shikita T, Zini N, Ognibene A, Santi S, Ferracini R, and Maraldi NM (1995) Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution. Eur J Cell Biol 68:226-239.
2. Batrakova EV, Lee S, Li S, Venn A, Alakhov V, and Kabanov A (1999) Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells. Pharm Res (N Y) 16:1373-1379.
3. Booser DJ, Esteva FJ, Rivera E, Valero V, Esparza-Guerra L, Priebe W, and Hortobagyi GN (2002) Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer. Cancer Chemother Pharmacol 50:6-8.
4. Bradford M (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding. Anal Biochem 72:248-254.
5. Chenevier P, Veyret B, Roux D, and Henry-Toulme N (2000) Interaction of cationic colloids at the surface of J774 cells: a kinetic analysis. Biophys J 79:1298-1309.
6. Cheung RY (2005) A Study of Alternative Delivery Strategies and Systems to Enhance the Therapeutic Effect and Cytotoxic Activity of Anticancer Agents. Ph.D. thesis, University of Toronto, Toronto, ON, Canada
7. Cheung RY, Rauth AM, Ronaldson P, Bendayan R, and Wu XY (2006) Cytotoxicity of microsphere-delivered mitomycin C and its combinations with doxorubicin against breast cancer cells. Eur J Pharm Biopharm 62:321-331.
8. de Verdiere AC, Dubernet C, Nemati F, Soma E, Appel M, Ferte J, Bernard S, Puisieux F, and Couvreur P (1997) Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action. Br J Cancer 76:198-205.
9. Dorr RT (1998) Antineoplastics, chemoprotectants and immunosuppressants, in Handbook of Clinical Drug Data (Anderson PO and Knoben JE eds) pp 157-212, Appleton & Lange, Stamford, CT.
10. Endicott JA and Ling V (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58:137-171.
11. Evers R, Kool M, van Deemter L, Janssen H, Calafat J, Oomen LC, Paulusma CC, Oude Elferink RP, Baas F, Schinkel AH, et al. (1998) Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin Investig 101:1310-1319.
12. Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53:615-627.
13. Jayanth P and Vinod L (2003) Dynamics of endocytosis and exocytosis of poly(D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm Res (N Y) 20:212-220.
14. Kabanov AV, Batrakova EV, and Alakhov VY (2002) Pluronic block copolymers for overcoming drug resistance in cancer. Adv Drug Del Rev 54:759-779.
15. Lam W, Leung CH, Chan HL, and Fong WF (2000) Toxicity and DNA binding of dextran-doxorubicin conjugates in multidrug-resistant KB-V1 cells: optimization of dextran size. Anticancer Drugs 11:377-384.
16. Lamprecht A, Yamamoto H, Takeuchi H, and Kawashima Y (2005) Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. J Pharmacol Exp Ther 315:196-202.
17. Lee KD, Hong K, and Papahadjopoulos D (1992) Recognition of liposomes by cells: in vitro binding and endocytosis mediated by specific lipid headgroups and surface charge density. Biochim Biophys Acta 1103:185-197.
18. Liu Z, Bendayan R, and Wu XY (2001) Triton-X-100-modified polymer and microspheres for reversal of multidrug resistance. J Pharm Pharmacol 53:1-12.
19. Longley DB and Johnston PG (2005) Molecular mechanisms of drug resistance. J Pathol 205:275-292.
20. Millenbaugh NJ, Wientjes MG, and Au JLS (2000) A pharmacodynamic analysis method to determine the relative importance of drug concentration and treatment time on effect. Cancer Chemother Pharmacol 45:265-272.
21. Miller CR, Bondurant B, McLean SD, McGovern KA, and O'Brien DF (1998) Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. Biochemistry 37:12875-12883.
22. Moghimi SM and Hunter AC (2000) Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. Trend Biotechnol 18:412-420.
23. Nori A, Jensen KD, Tijerina M, Kopeckova P, and Kopecek J (2003) Subcellular trafficking of HPMA copolymer-TAT conjugates in human ovarian carcinoma cells. J Control Release 91:53-59.
24. Ramge P, Unger PE, and Oltrogge JB (2000) Polysorbate-80 coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human, bovine and murine primary brain capillary endothelial cells. Eur J Neurosci 12:1935-1940.
25. Romsicki Y and Sharom FJ (1999) The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter. Biochemistry 38:6887-6896.
26. Ronaldson TP, Bendayan M, Gingras D, Piquette-Miller M, and Bendayan R (2004) Cellular localization and functional expression of P-glycoprotein in rat astrocyte cultures. J Neurochem 89:788-800.
27. Skeel RT (2003) Selection of treatment for the patient with cancer, in Handbook of Cancer Chemotherapy (Skeel RT ed) pp 46-52, Lippincott Williams & Wilkins, Philadelphia, PA.
28. Soma CE, Dubernet C, Barratt G, Nemati F, Appel M, Benita S, and Couvreur P (1999) Ability of doxorubicin-loaded nanoparticles to overcome multidrug resistance of tumor cells after their capture by macrophages. Pharm Res (N Y) 16:1710-1716.
29. Tack DK, Palmieri FM, and Perez EA (2004) Anthracycline vs nonanthracycline adjuvant therapy for breast cancer. Oncology 18:1367-1376.
30. Templeton NS (2002) Cationic liposome-mediated gene delivery in vivo. Biosci Rep 22:283-295.
31. Thierry AR, Vige D, Coughlin SS, Belli JA, Dritschilo A, and Rahman A (1993) Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes. FASEB J 7:572-579.
32. Tipton JM (2003) Side effects of cancer chemotherapy, in Handbook of Cancer Chemotherapy (Skeel RT ed) pp 561-580, Lippincott Williams & Wilkins, Philadelphia, PA.
33. Veldman RJ, Koning GA, van Hell A, Zerp S, Vink SR, Storm G, Verheij M, and van Blitterswijk WJ (2005) Coformulated N-octanoyl-glucosylceramide improvescellular delivery and cytotoxicity of liposomal doxorubicin. J Pharmacol Exp Ther 315:704-710.
34. Wielinga PR, Westerhoff HV, and Lankelma J (2000) The relative importance of passive and P-glycoprotein mediated anthracycline efflux from multidrugresistant cells. Eur J Biochem 267:649-657.
35. Wong HL, Bendayan R, Rauth AM, and Wu XY (2004) Development of solid lipid nanoparticles containing ionically-complexed chemotherapeutic drugs and chemosensitizers. J Pharm Sci 93:1993-2004.
36. Wong HL, Rauth AM, Bendayan R, and Wu XY (2005) Novel solid lipid nanoparticles formulations increase the cytotoxicity and prolong the cellular accumulation of doxorubicin in human multidrug-resistant breast cancer cells (Abstract). Proc AACR 45:1433.
37. Wong HL, Rauth AM, Bendayan R, and Wu XY (2006) A new solid lipid nanoparticle formulation increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm Res (N Y), in press.
38. Zhang K, Huang H, Yang G, Shaw J, Yip C, and Wu XY (2004) Characterization of nanostructure of stimuli-response polymeric composite membranes. Biomacromolecules 5:1248-1255.
39. Zilfou JT and Smith CD (1995) Differential interactions of cytochalasins with P-glycoprotein. Oncol Res 7:435-443.